Skip to main content
Realcan Pharmaceutical Group Co.,Ltd. logo

Realcan Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 002589 ISIN · CNE1000013X5 LEI · 300300YI5IV3FBRRSJ48 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,678 across all filing types
Latest filing 2024-04-29 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002589

About Realcan Pharmaceutical Group Co.,Ltd.

https://www.realcan.cn

Realcan Pharmaceutical Group Co., Ltd. specializes in the distribution of pharmaceutical products, medical devices, and healthcare consumables. The company operates an extensive supply chain network, providing integrated logistics and distribution services primarily to medical institutions and healthcare providers. Its core operations include the procurement, storage, and delivery of a wide range of medical supplies, supported by advanced information management systems and cold-chain logistics capabilities. Realcan also offers value-added services such as hospital supply chain optimization, third-party logistics, and financial solutions tailored to the healthcare industry. By focusing on a direct-to-hospital distribution model, the company aims to enhance the efficiency of medical supply procurement and ensure the timely delivery of critical healthcare products.

Recent filings

Filing Released Lang Actions
独立董事述职报告（孙考祥）
Board/Management Information Classification · 95% confidence The document is an independent director's annual performance report for the year 2023, detailing the director's activities, attendance at board and shareholder meetings, oversight on financial reporting, internal controls, and other governance-related duties. It is not a financial report like an annual or interim report, nor is it a regulatory filing or announcement. The content focuses on the director's role and responsibilities, which aligns with Board/Management Information filings. The document length is 2658 characters, which is relatively short but contains substantive content about the director's duties and opinions rather than just an announcement. Therefore, the best classification is Board/Management Information (MANG).
2024-04-29 Chinese
监事会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a formal announcement of resolutions passed at the seventh meeting of the fifth Supervisory Board of Ruikang Pharmaceutical Group Co., Ltd. It includes approvals of the 2023 Annual Report and its summary, the 2023 Supervisory Board Work Report, the 2023 Financial Final Accounts Report and 2024 Financial Budget Report, the 2023 Internal Control Self-Evaluation Report, the 2023 Profit Distribution Plan, the 2024 Q1 Report, and other corporate governance matters. The document repeatedly states that these reports and proposals will be submitted to the 2023 Annual General Meeting for approval. The document itself does not contain the full annual report or detailed financial statements but rather resolutions approving these reports and plans. The length is 3428 characters, which is relatively short and consistent with an announcement rather than a full report. The document is a formal announcement of meeting resolutions and approvals, not the full annual report or financial report itself. Therefore, it fits best into the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it reports the voting results of the Supervisory Board meeting on various reports and proposals related to the annual report and other corporate matters.
2024-04-29 Chinese
关于实际控制人股份质押和解除质押的公告
Major Shareholding Notification Classification · 95% confidence The document is an announcement regarding the pledge and release of shares by the actual controller of the company, including detailed tables of share pledges, release dates, and related shareholder information. It does not contain financial statements, management discussion, or audit information. It is a regulatory announcement about share pledging activities by a controlling shareholder. This fits the category of Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership or related shareholding activities such as pledges. The document length is short and focused on share pledge details, not a full report or earnings release.
2024-04-07 Chinese
关于全资子公司为上市公司提供担保的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from 瑞康医药集团股份有限公司 regarding guarantees provided by its wholly-owned subsidiaries for the listed company. It details the guarantee amounts, involved banks, approval procedures, and the impact on the company. The document is relatively short (2804 characters) and focuses on a specific financing-related event (providing guarantees for credit facilities). It does not contain comprehensive financial statements or detailed financial performance data typical of annual or interim reports. It is not a report publication announcement since it contains substantive information about the guarantee event itself. The content aligns best with a Capital/Financing Update (CAP) as it relates to financing activities and credit guarantees. Therefore, the appropriate classification is CAP with high confidence.
2024-02-26 Chinese
关于实际控制人部分股份质押的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the pledge of shares by the company's actual controller and major shareholders. It details the number of shares pledged, the proportion of shares pledged relative to total holdings and company capital, the risk assessment related to the pledge, and compliance with disclosure regulations. There are no financial statements, earnings data, or management discussion of financial results. The document is a regulatory announcement about share pledging activity, which fits the category of Capital/Financing Update (CAP). The document length is short (2182 characters), and it is not a report publication announcement or certification. Therefore, the classification is Capital/Financing Update (CAP) with high confidence.
2024-02-07 Chinese
关于公司新增对外担保的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from 瑞康医药集团股份有限公司 regarding the company's new external guarantees (新增对外担保). It details the guarantee amounts, the parties involved, financial conditions of the guaranteed companies, and opinions from the board and supervisory committee. The document is a formal announcement about a specific corporate action (providing guarantees) rather than a financial report, earnings release, or management discussion. It does not contain comprehensive financial statements or quarterly/yearly results. It is also not a regulatory certification or a report publication notice. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous corporate announcements that do not fit other specific categories.
2024-02-05 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.